Unlocking the potential of deferoxamine: a systematic review on its efficacy and safety in alleviating myocardial ischemia-reperfusion injury in adult patients following cardiopulmonary bypass compared to standard care
Therapeutic Advances in Cardiovascular Disease · 2024
DOI: 10.1177/17539447241277382 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Therapeutic Advances in Cardiovascular Disease, 2024. Verfasst von Aashish Lamichhane und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Medical Sciences, Bharatpur 44200, Nepal. Hauptthemen laut MEDLINE: Cardiopulmonary Bypass, Deferoxamine, Myocardial Reperfusion Injury, Oxidative Stress. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Reperfusion injury, characterized by oxidative stress and inflammation, poses a significant challenge in cardiac surgery with cardiopulmonary bypass (CPB). Deferoxamine, an iron-chelating compound, has shown promise in mitigating reperfusion injury by inhibiting iron-dependent lipid peroxidation and reactive oxygen species (ROS) production.
Objectives
The objective of our study was to analyze and evaluate both the efficacy and safety of a new and promising intervention, that is, deferoxamine for ischemia-reperfusion injury (I/R).
Design
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines are used to perform the study. Data sources and methods: We conducted a systematic review following PRISMA guidelines to assess the efficacy and safety of deferoxamine in reducing I/R injury following CPB. A comprehensive search of electronic databases, namely, PubMed, Scopus, and Embase, yielded relevant studies published until August 18, 2023. Included studies evaluated ROS production, lipid peroxidation, cardiac performance, and morbidity outcomes.
Results
(a) ROS production: Multiple studies demonstrated a statistically significant decrease in ROS production in patients treated with deferoxamine, highlighting its potential to reduce oxidative stress. (b) Lipid peroxidation: Deferoxamine was associated with decreased lipid peroxidation levels, indicating its ability to protect cardiac tissue from oxidative damage during CPB. (c) Cardiac performance: Some studies reported improvements in left ventricular ejection fraction and wall motion score index with deferoxamine.
Conclusion
Our review shows that deferoxamine is an efficacious and safe drug that can be used to prevent myocardial I/R injury following CPB. It also highlights the need for trials on a larger scale to develop potential strategies and guidelines on the use of deferoxamine for I/R injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Medical Sciences, Bharatpur 44200, Nepal.
- College of Medical Sciences, Bharatpur, Nepal.
ORCID-Profile: Aashish Lamichhane
Zitieren
APA
Lamichhane, A., Sharma, S., Bastola, B., Chhusyabaga, B., Shrestha, N., & Poudel, P. (2024). Unlocking the potential of deferoxamine: a systematic review on its efficacy and safety in alleviating myocardial ischemia-reperfusion injury in adult patients following cardiopulmonary bypass compared to standard care. Therapeutic Advances in Cardiovascular Disease. https://doi.org/10.1177/17539447241277382
Vancouver
Lamichhane A, Sharma S, Bastola B, Chhusyabaga B, Shrestha N, Poudel P. Unlocking the potential of deferoxamine: a systematic review on its efficacy and safety in alleviating myocardial ischemia-reperfusion injury in adult patients following cardiopulmonary bypass compared to standard care. Therapeutic Advances in Cardiovascular Disease. 2024. doi:10.1177/17539447241277382
BibTeX
@article{Lamichhane2024,
author = {Lamichhane, Aashish and Sharma, Sadish and Bastola, Bishwas and Chhusyabaga, Bikesh and Shrestha, Nabin and Poudel, Prajwal},
title = {Unlocking the potential of deferoxamine: a systematic review on its efficacy and safety in alleviating myocardial ischemia-reperfusion injury in adult patients following cardiopulmonary bypass compared to standard care},
journal = {Therapeutic Advances in Cardiovascular Disease},
year = {2024},
doi = {10.1177/17539447241277382}
}
EUVIMED